Business
Suda Pharmaceuticals share price soars 200% on TGA approval – Motley Fool Australia
The Suda Pharmaceuticals share price is soaring over 200% following TGA approval for its insomnia treatment product, ZolpiMist.
The Suda Pharmaceuticals Ltd(ASX: SUD) share price has soared 207.4% today, at the time of writing. The surge came following the company’s announcement that its Zolpimist product has been approved by the TGA (Therapeutic Goods Administration). ZolpiMist is an oral spray for the treatment of insomnia.
In an investor presentation released by Suda Pharmaceuticals earlier this month, the company estimated the market for insomnia treatments will be approximately US$4 billion by 2026. Furthermore, a…
-
Noosa News22 hours agoDevastating update in search for missing Queensland mother Tayla Spies as police find human remains near her ute
-
Noosa News23 hours agoNicole Kidman Is Back in Wellness Guru Mode: ‘Nine Perfect Strangers’ Season Two Will Hit Your Streaming Queue in May
-
Business20 hours agoOwn the world with these 3 global ASX ETFs
-
General22 hours agoHousing affordability. The crisis the major parties are too scared to fix